As of August 1, 2020, patients with midgut, GEP-NETs will now be eligible for treatment with LUTATHERA® [lutetium (177Lu) oxodotreotide]. This listing covers adult patients with somatostatin receptor-positive (SSR+) midgut [...]
HOOFING IT - The summer-long fundraiser launched at Peggy's Cove on July 1st. Sharon Needham, lung neuroendocrine cancer survivor and advocate; family, friends, supporters kicked-off HOOFING IT with a [...]
#HoofingIt across Canada to fight one of the fastest-growing class of cancers Canadian Neuroendocrine Tumour Society (CNETS) launches fundraising challenge at Peggy’s Cove July 1, 2020 HALIFAX [...]
Advanced Accelerator Applications Announces Health Canada Approval of NETSPOT® Diagnostic Imaging Agent Kit to Detect Neuroendocrine Tumours NETSPOT® is the first and only kit for the preparation of [...]
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection) Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for [...]
It is my pleasure to once again share a quick note on the work of CNETS Canada over the past several months. As always, we have been incredibly busy [...]
CNETS Canada is looking for volunteers to join our NET Cancer Awareness Committee. Specific knowledge of NETs or charitable experience is not required but will be considered an asset. [...]
68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have [...]
Join CNETS Canada 2019 National NET Patient Conference's video & audio conference by clicking the following link: https://freeman.meetngreet.ca/join/x1GxoRj3UO 2019 NATIONAL NET PATIENT CONFERENCE LIVE-STREAM Saturday April 6, 2019 from [...]
As we start 2019 we bid farewell to a long-time board member and welcome three new board members to CNETS Canada’s Board of Directors. We extend our heartfelt gratitude to [...]